

Publisher: John Wiley & Sons Inc
E-ISSN: 1097-0215|137|4|903-910
ISSN: 0020-7136
Source: INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.4, 2015-08, pp. : 903-910
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes
Annals of Medicine, Vol. 45, Iss. 8, 2013-12 ,pp. :





